NCT03095495

Brief Summary

The enrolled RSV-bronchiolitis patients will be randomized into two arms , the early HHHFNC group and the standard therapy group with rescue HHHFNC to study the efficacy of this treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
28

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Aug 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 6, 2017

Completed
23 days until next milestone

First Posted

Study publicly available on registry

March 29, 2017

Completed
1.4 years until next milestone

Study Start

First participant enrolled

August 14, 2018

Completed
5.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 28, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 28, 2024

Completed
Last Updated

September 19, 2024

Status Verified

May 1, 2024

Enrollment Period

5.8 years

First QC Date

March 6, 2017

Last Update Submit

September 8, 2024

Conditions

Keywords

Heated Humidified High Flow Nasal Cannula (HHHFNC)Low Flow Nasal CannulaBronchiolitisRespiratory Syncytial Virus (RSV)Respiratory FailureHigh Flow Nasal Cannula (HFNC)Lung Diseases, Obstructive

Outcome Measures

Primary Outcomes (1)

  • The rate of Pediatric Intensive Care Unit (PICU) admissions

    The rate of Pediatric Intensive Care Unit admissions

    Through study completion, an average of 3 year

Secondary Outcomes (5)

  • Mean length of stay (LOS)

    Through study completion, an average of 3 year

  • Bronchiolitis Severity Score (BSS)

    Up to 72 hours

  • Percentage of revisit, infirmary short-stay and admission to the hospital or PICU

    2 weeks after discharge

  • Transcutaneous Partial Pressure of Carbon Dioxide (PtcCO2)

    Up to 72 hours

  • Percentage of patients who are on the standard therapy arm and required ICU admission, but improved after the rescue HHHFNC in the ED

    1 hour after starting of rescue HHHFNC

Study Arms (2)

Early use of HHHFNC

EXPERIMENTAL

Heated Humidified High Flow Nasal Cannula

Device: Heated Humidified High Flow Nasal Cannula

Standard Therapy and Rescue HHHFNC

ACTIVE COMPARATOR

Low Flow Nasal Cannula only if the patient needs oxygenation and Rescue HHHFNC if the patient needs PICU

Device: Heated Humidified High Flow Nasal CannulaDevice: Standard Therapy (Low Flow Nasal Cannula)

Interventions

HHHFNC therapy is a simple to use system that delivers warm and moist air/oxygen mixture at high flow rates that generate positive airway pressure

Early use of HHHFNCStandard Therapy and Rescue HHHFNC

will be used only if the patient needs oxygenation and Rescue HHHFNC will be used if the patient needs PICU

Standard Therapy and Rescue HHHFNC

Eligibility Criteria

AgeUp to 3 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Previously healthy infants with age 0-3 months and gestational age ≥30 weeks admitted to the short stay unit with RSV positive bronchiolitis and clinical severity score ≥4 on Wang clinical severity scale.

You may not qualify if:

  • Gestational age less than 30 weeks.
  • Previous history of wheezing.
  • Use of steroid within 48 hours of presentation.
  • History of chronic lung disease.
  • Infants admitted directly to ICU.
  • Prior invasive or non-invasive ventilatory support.
  • Tracheostomy.
  • Nasogastric tubes in situ on admission.
  • Upper airway abnormality (like choanal atresia and midfacial anomalies).
  • Immunodeficient children.
  • History of cardiac disease, renal disease or liver disease.
  • History of neuromuscular disorder.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Alsadd Pediatric Emergency Center

Doha, Qatar

Location

MeSH Terms

Conditions

BronchiolitisRespiratory InsufficiencyLung Diseases, Obstructive

Condition Hierarchy (Ancestors)

BronchitisRespiratory Tract InfectionsInfectionsBronchial DiseasesRespiratory Tract DiseasesLung DiseasesRespiration Disorders

Study Officials

  • Khalid Alansari, MD

    Hamad Medical Corporation

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 6, 2017

First Posted

March 29, 2017

Study Start

August 14, 2018

Primary Completion

May 28, 2024

Study Completion

May 28, 2024

Last Updated

September 19, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will not share

Locations